Geron (MIL:1GERN) Marketable Securities: €210.6 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1GERN Geron Corp MIL:1GERN
20 GF Score
Price €1.22
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Geron Marketable Securities?

Geron MIL:1GERN 20 Marketable Securities is €210.6 Mil as of Mar. 2026. GuruFocus rates MIL:1GERN with a GF Score™ of 20/100 (Possible Value Trap). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Geron's Marketable Securities for the quarter that ended in Mar. 2026 was €210.6 Mil.

Geron's annual Marketable Securities increased from Dec. 2023 (€241.8 Mil) to Dec. 2024 (€312.8 Mil) but then declined from Dec. 2024 (€312.8 Mil) to Dec. 2025 (€239.4 Mil).

Geron  (MIL:1GERN) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Geron Marketable Securities Related Terms

Geron Marketable Securities Historical Data

* Premium members only.

The historical data trend for Geron's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geron Marketable Securities Chart

Geron Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 131.73 109.41 241.79 312.81 239.43

Geron Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 289.65 268.98 257.66 239.43 210.63
MIL:1GERN
20GF Score
Geron Corp MIL:1GERN
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Geron Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €210.6 Mil mean?
Geron (MIL:1GERN) has a Marketable Securities of €210.6 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Geron and its competitors.
Is Geron's Marketable Securities too high?
Geron's current Marketable Securities is €210.6 Mil. Overall, Geron has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's Marketable Securities compare to PHAT and KURA?
Geron's Marketable Securities of €210.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Geron and its competitors. Geron's current Marketable Securities is €210.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (MIL:1GERN) is currently considered Possible Value Trap. The current Marketable Securities is €210.6 Mil. Geron's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Geron (MIL:1GERN), the current Marketable Securities is €210.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Geron Business Description

Other Exchanges GERN:USA0IV3:UKGON:Germany
Address 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
20GF Score

Get the complete analysis for MIL:1GERN

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.22
Price